公开(公告)号：US20190337921A1

公开(公告)日：2019-11-07

申请号：US16349508

申请日：2017-11-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu ,  Lorna Helen Mitchell ,  Nicholas Larsen ,  Nathalie Rioux

IPC: C07D401/06 ,  C07D209/08 ,  C07D401/14 ,  A61P35/00

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US20200255415A1

公开(公告)日：2020-08-13

申请号：US16349479

申请日：2017-11-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Bock ,  Ming-Hong Hao ,  Manav Korpal ,  Vijay Kumar Nyavanandi ,  Xiaoling Puyang ,  Susanta Samajdar ,  Peter Gerard Smith ,  John Wang ,  Guo Zhu Zheng ,  Ping Zhu ,  Lorna Helen Mitchell ,  Nicholas Larsen ,  Nathalie Rioux ,  Sudeep Prajapati ,  Dominic Reynolds ,  Morgan O'Shea ,  Thiwanka Samarakoon

IPC: C07D413/14 ,  A61P35/00 ,  C07D231/56 ,  C07D401/10 ,  C07D401/14 ,  C07D401/12 ,  C07D413/12 ,  C07D403/10

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.